Table 2.
Baseline characteristics and prescribing patterns at commencement of first biologic
| ILAR subtype | SJIA | OJIA | RF− PJIA | RF+ PJIA | ERA | JPsA | Subtype unknown | Total | P-value |
|---|---|---|---|---|---|---|---|---|---|
| Number | 11 (5) | 38 (17) | 19 (8) | 36 (16) | 24 (11) | 26 (12) | 71 (31) | 225 | |
| Age, yearsa | 26 (22–31) | 28.5 (23–37) | 29 (21–36) | 31 (22–42) | 34 (22–39) | 29 (25–39) | 36 (24–42) | 31 (23–39) | 0.38 |
| Female, % | 82 | 82 | 95 | 94 | 17 | 62 | 82 | 76 | <0.001 |
| Disease duration, years | 14 (8–22) | 20 (15–26) | 20 (11–24) | 16.5 (9–29) | 19 (8–28) | 19 (11–30) | 25 (15–31) | 21 (12–30) | 0.88 |
| Smoking status | |||||||||
| Never | 8 (73) | 27 (71) | 9 (47) | 25 (69) | 15 (63) | 11 (42) | 37 (52) | 132 (59) | 0.12 |
| Previously | 0 | 1 (2.5) | 5 (26) | 5 (14) | 2 (8) | 6 (23) | 16 (23) | 35 (16) | |
| Current | 2 (18) | 9 (24) | 4 (21) | 6 (17) | 7 (29) | 9 (35) | 18 (25) | 55 (24) | |
| Missing | 1 (9) | 1 (2.5) | 1 (5) | 0 | 0 | 0 | 0 | 3 (1) | |
| Co-morbiditiesb | |||||||||
| PUD | 1 (10) | 0 | 0 | 1 (3) | 2 (8) | 0 | 3 (4) | 7 (3) | 0.19 |
| Depression | 2 (20) | 5 (13) | 3 (16) | 3 (8) | 8 (33) | 6 (23) | 15 (21) | 42 (19) | 0.20 |
| Asthma | 0 | 3 (8) | 2 (11) | 5 (14) | 1 (4) | 2 (8) | 9 (13) | 22 (10) | 0.70 |
| Baseline DMARDs | |||||||||
| None | 3 (27) | 12 (31) | 9 (47) | 12 (33) | 6 (25) | 10 (38) | 25 (35) | 78 (35) | |
| MTX monotherapy | 7 (64) | 19 (50) | 6 (32) | 14 (39) | 12 (50) | 11 (42) | 29 (41) | 98 (44) | 0.89 |
| MTX combinationc | 1 (9) | 3 (8) | 1 (5) | 4 (11) | 4 (17) | 3 (12) | 11 (15) | 27 (12) | |
| Other | 0 | 4 (11) | 3 (16) | 5 (14) | 2 (8) | 2 (8) | 6 (9) | 22 (9) | |
| Total number of DMARDs prior to first biologic | 3 (2–4) | 4 (3–5) | 3 (2–6) | 4 (2–6) | 2 (2–4.5) | 3 (2–5) | 4 (3–5) | 3 (2–5) | 0.54 |
| Primary biologic | |||||||||
| Etanercept | 6 (55) | 17 (45) | 14 (73) | 18 (50) | 12 (50) | 17 (65) | 26 (37) | 110 (49) | |
| Infliximab | 2 (18) | 13 (34) | 2 (11) | 8 (22) | 9 (37.5) | 6 (23) | 24 (34) | 64 (28) | 0.60 |
| Adalimumab | 3 (27) | 8 (21) | 3 (16) | 9 (25) | 3 (12.5) | 3 (12) | 21 (29) | 50 (22) | |
| Anakinra | 0 | 0 | 0 | 1 (3) | 0 | 0 | 0 | 1 (1) | |
| Total biologics | |||||||||
| 1 | 6 (55) | 18 (47) | 14 (74) | 18 (50) | 12 (50) | 17 (65) | 27 (38) | 112 (50) | 0.63 |
| 2 | 2 (18) | 12 (32) | 2 (10) | 9 (25) | 9 (38) | 6 (23) | 24 (34) | 64 (28) | |
| ≥3 | 3 (27) | 8 (21) | 3 (16) | 9 (25) | 3 (12) | 3 (12) | 20 (28) | 49 (22) | |
| Biologic therapy used ever | |||||||||
| Etanercept | 8 (73) | 27 (71) | 16 (84) | 23 (64) | 17 (71) | 19 (73) | 39 (55) | 110 (72) | |
| Infliximab | 3 (27) | 16 (42) | 5 (26) | 10 (28) | 9 (37.5) | 7 (27) | 30 (42) | 50 (32) | |
| Adalimumab | 5 (45) | 16 (42) | 8 (42) | 15 (42) | 7 (29) | 6 (23) | 33 (46) | 57 (37) | |
| Anakinra | 1 (9) | 1 (2.5) | 0 | 1 (3) | 0 | 0 | 1 (1) | 3 (2) | |
| Rituximab | 0 | 4 (11) | 1 (5) | 5 (14) | 1 (4) | 1 (4) | 2 (3) | 12 (8) | |
| Abatacept | 0 | 0 | 0 | 0 | 0 | 0 | 1 (1) | 0 | |
| Tocilizumab | 0 | 0 | 0 | 0 | 0 | 0 | 1 (1) | 0 | |
All values median (IQR) or n (%). SJIA: systemic-onset JIA; OJIA: oligoarticular JIA; RF− PJIA: RF-negative polyarticular JIA; RF+ PJIA: RF-positive polyarticular JIA; JPsA: psoriatic JIA; UnJIA: unclassifiable JIA; PUD: peptic ulcer disease. aMedian age in years at commencement of the first biologic. bNo patients were reported as having malignancy, tuberculosis or demyelinating disease. cMTX combination: MTX prescribed in combination with one or more other DMARDs.